Danazol Therapy in Myelodysplasia

Douglas B. Cines, PETER A CASSILETH, JOSEPH E. KISS
In: Annals of Internal Medicine · 1985 · vol. 103(1) , pp. 58–60 · doi:10.7326/0003-4819-103-1-58 · PMID:4003989 · W1991796424
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Danazol therapy increased platelet counts and stopped bleeding in myelodysplastic patients with severe thrombocytopenia and elevated platelet-associated IgG.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Platelet-associated IgG was markedly elevated in three patients with myelodysplasia and severe thrombocytopenia that had become refractory to platelet transfusions. The patients were treated with danazol because of its efficacy in treating immune thrombocytopenic purpura where platelet destruction is primarily mediated by IgG autoantibodies. After danazol therapy, the platelet counts of each patient rose and clinical bleeding stopped, and a decline in hemolysis was seen in two patients. Danazol probably impeded the peripheral clearance of cells by macrophages; however, a beneficial effect of danazol on hematopoiesis cannot be excluded.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (16)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-09-11T06:32:28.951138+00:00
License: CC0 · commercial use OK